Skip to content

CG Oncology CGON Total costs & expenses

Total costs & expenses at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$114M+40.8%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$103.61M+38.3%
Exelixis logo
ExelixisEXEL
$359.47M-2.5%
Gilead Sciences logo
Gilead SciencesGILD
Biogen logo
BiogenBIIB
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Revenue$1.1M+1,983%
Operating income-$66.4M-57.3%
Net income-$60.2M-74.7%
EPS (diluted)-$0.71-57.8%

Balance sheet

See full
Cash & equivalents$33.7M-18.7%
Total debt$7.6M+631%
Total equity$1.1B+54.9%
Total assets$1.1B+55.9%

Cash flow

See full
Operating cash flow-$56.9M-94.5%
CapEx$304.0K+1,800%
Free cash flow-$57.2M-95.4%

Valuation

See full
Market cap$5.39B+206%
Enterprise value$5.36B+212%
P/S1,062.4×-1,596×

Profitability

See full
Operating margin-4,239%-1,872pp
Net margin-3,682.6%-1,601pp
FCF margin-3,163.8%-1,351pp

Returns & leverage

See full
Return on equity-20.8%+7.1pp
Debt / equity0.0×
Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:OperatingCostsAndExpenses.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's total costs & expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CG Oncology's total costs & expenses?
CG Oncology (CGON) reported total costs & expenses of $67.47M in Q1 2026.
How has CG Oncology's total costs & expenses changed year-over-year?
CG Oncology's total costs & expenses increased by 59.7% year-over-year, from $42.26M to $67.47M.
What does total costs & expenses mean?
This metric aggregates all operating and non-operating costs incurred by the company to support its business activities, including research and development, general administration, and production costs. It provides a comprehensive view of the total capital outflow required to sustain operations and clinical development programs. Investors use this to evaluate the company's overall burn rate and operational efficiency.